Fc-PYY3-36 /Fc-GLP-1R agonist (Astrazeneca )

N/A

Report date: 2026/04/10 20:01:49

Base Information

Drug NameFc-PYY3-36 /Fc-GLP-1R agonist (Astrazeneca )
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion protein
Mechanisms of ActionNeuropeptide Y receptor type 2 agonistsGlucagon-like peptide 1 receptor agonists
TargetsNeuropeptide Y receptor type 2Glucagon-like peptide 1 receptor
Therapy Area/IndicationsObesityDiabetes Mellitus
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesAstrazeneca Plc
China Registration ClassN/A

Develop Information

Active CompaniesAstrazeneca Plc
Inactive CompaniesN/A
Active IndicationsObesityDiabetes Mellitus
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A